Open AccessReduced prehepatic extraction of nicardipine in the presence of pioglitazone in rats
Author(s) -
Choi JunShik,
Koh YoungYoup,
Chung JoongHwa,
Choi DongHyun,
Han HyoKyung
Publication year - 2008
Publication title -
journal of pharmacy and pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.745
H-Index - 118
eISSN - 2042-7158
pISSN - 0022-3573
DOI - 10.1211/jpp.60.10.0017
Subject(s) - nicardipine , pioglitazone , pharmacokinetics , bioavailability , pharmacology , oral administration , medicine , chemistry , endocrinology , diabetes mellitus , blood pressure , type 2 diabetes
This study investigated the effect of pioglitazone on the pharmacokinetics of oral and i.v. nicardipine in rats. Pharmacokinetic parameters were determined after nicardipine was administered orally (12 mg kg −1 ) or i.v. (4 mg kg −1 ) with or without a single dose of oral pioglitazone (0.3 or 1.0 mg kg −1 ). Compared with the control group given nicardipine alone, coadministration of pioglitazone significantly decreased the total plasma clearance of orally administered nicardipine (by 40.4–46.3%, P < 0.05) and significantly increased the area under the plasma concentration‐time curve (by 81.8–96.3%) and the peak plasma concentration, C max (by 56.5–66.8%). T max and the terminal plasma half‐life of nicardipine were not affected, however. Coadministration of oral pioglitazone did not affect the pharmacokinetics of i.v. nicardipine, implying that pioglitazone may mainly decrease the prehepatic extraction of nicardipine during intestinal absorption. In conclusion, pioglitazone significantly enhanced the oral bioavailability of nicardipine in rats by reducing its presystemic clearance.